Last reviewed · How we verify
Magnesium sulfate 24 hours
Magnesium sulfate acts as a central nervous system depressant and smooth muscle relaxant by blocking neuromuscular transmission and reducing acetylcholine release at the neuromuscular junction.
Magnesium sulfate acts as a central nervous system depressant and anticonvulsant by blocking N-methyl-D-aspartate (NMDA) receptors and reducing neuromuscular transmission. Used for Seizure prophylaxis in preeclampsia and eclampsia, Premature labor (tocolysis), Severe asthma exacerbation.
At a glance
| Generic name | Magnesium sulfate 24 hours |
|---|---|
| Sponsor | Instituto Materno Infantil Prof. Fernando Figueira |
| Drug class | NMDA receptor antagonist; tocolytic agent; anticonvulsant |
| Target | NMDA receptor; L-type calcium channels |
| Modality | Small molecule |
| Therapeutic area | Obstetrics; Neurology; Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Magnesium ions compete with calcium at voltage-gated calcium channels and the neuromuscular junction, reducing excitability of nerves and muscles. This results in vasodilation, anticonvulsant effects, and smooth muscle relaxation. The drug is commonly used in obstetrics for seizure prophylaxis in preeclampsia/eclampsia and as a tocolytic agent to delay preterm labor.
Approved indications
- Seizure prophylaxis in preeclampsia and eclampsia
- Tocolytic agent for delay of preterm labor
- Magnesium supplementation in deficiency states
Common side effects
- Flushing
- Sweating
- Hypotension
- Depressed reflexes
- Muscle weakness
- Respiratory depression (at high doses)
- Hypermagnesemia
Key clinical trials
- Biomarkers in Management of Post Partum Preeclampsia (PHASE4)
- Rate, Rhythm or Risk Control for New-onset Supraventricular Arrhythmia During Septic Shock: a Randomized Controlled Trial (NA)
- Ringer Acetate Based Modified Del Nido Cardioplegia Solution Versus HTK Solution Cardioplegia Solution in Cardiac Surgery (PHASE3)
- Comparing Intravenous and Intramuscular Magnesium Sulphate for Preventing Seizure Recurrence in Women With Eclampsia (PHASE4)
- Magnesium Infusion for Pain Management in Critically Ill Trauma Patients (PHASE4)
- Early Intravenous Magnesium Sulfate and Its Impact on Cerebral Vasospasm in Traumatic Subarachnoid Hemorrhage (EARLY_PHASE1)
- The Efface of Lidocaine vs. Magnesium Sulphate in the Management of Pain After Laparoscopic Cholecystectomy (PHASE1)
- The Efface of Ketamine vs. Magnesium Sulphate in the Management of Pain After Laparoscopic Cholecystectomy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: